Public Health Relevance

--Overall The Mays Cancer Center (MCC) at the University of Texas Health San Antonio (UT Health SA) is the National Cancer Institute-designated Cancer Center (NCICC) for a 38-county region of Central and South Texas, a region of 45,926 square miles with 4.9 million individuals who have a unique set of cancer-related challenges. The population in this catchment area is predominantly Hispanic, the fastest growing demographic in the United States (U.S.). The mission of the MCC is to reduce the cancer burden in Central and South Texas through the highest quality cancer care with expanded treatment options from our early phase clinical trials, ground- breaking cancer research aimed at reducing the incidence and mortality of cancer as well as improving treatment options, education of the future leaders of cancer scientists and clinicians, and cancer prevention programs that focus on our unique population. The MCC strives to be the institution of choice for cancer care in South Texas, a highly-productive research institution that attracts and retains the best cancer scientists, is the institution of choice for cancer education, and an organization devoted to reducing the burden of cancer in our region. The MCC has continued its focus on serving our unique South Texas population which is predominantly Hispanic (69%). The population of San Antonio?s metropolitan area is about 63% Hispanic, while parts of South Texas included in our catchment area are more than 90% Hispanic. Our goal is for the MCC to be a national resource where personalized, culturally-sensitive clinical care and scientific discovery will be conducted, focusing on the unique population of San Antonio and South Texas, to be used as the precepts for cancer control for the U.S. which, with changing demographics, will face many of the current challenges of our region in the future.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA054174-25
Application #
10025084
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Roberson, Sonya
Project Start
1997-08-01
Project End
2025-07-31
Budget Start
2020-08-13
Budget End
2021-07-31
Support Year
25
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Texas Health Science Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Yu, Xiaojie; Zhang, Yiqiang; Cavazos, David et al. (2018) miR-195 targets cyclin D3 and survivin to modulate the tumorigenesis of non-small cell lung cancer. Cell Death Dis 9:193
Chen, Chen; Zhao, Shujie; Karnad, Anand et al. (2018) The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol 11:64
Abbott, Jamie A; Meyer-Schuman, Rebecca; Lupo, Vincenzo et al. (2018) Substrate interaction defects in histidyl-tRNA synthetase linked to dominant axonal peripheral neuropathy. Hum Mutat 39:415-432
Guo, Jiayan; Kim, Hong Seok; Asmis, Reto et al. (2018) Interactions of ? tubulin isotypes with glutathione in differentiated neuroblastoma cells subject to oxidative stress. Cytoskeleton (Hoboken) 75:283-289
Liss, Michael A; Chen, Yidong; Rodriguez, Ronald et al. (2018) Immunogenic Heterogeneity of Renal Cell Carcinoma With Venous Tumor Thrombus. Urology :
Zhu, Haiyan; Xia, Lu; Shen, Qi et al. (2018) Differential effects of GLI2 and GLI3 in regulating cervical cancer malignancy in vitro and in vivo. Lab Invest 98:1384-1396
Zeno, Wade F; Baul, Upayan; Snead, Wilton T et al. (2018) Synergy between intrinsically disordered domains and structured proteins amplifies membrane curvature sensing. Nat Commun 9:4152
Mahalingam, Devalingam; Goel, Sanjay; Aparo, Santiago et al. (2018) A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma. Cancers (Basel) 10:
Yu, Xiaojie; Zhang, Yiqiang; Ma, Xiuye et al. (2018) miR-195 potentiates the efficacy of microtubule-targeting agents in non-small cell lung cancer. Cancer Lett 427:85-93
Ankerst, Donna P; Goros, Martin; Tomlins, Scott A et al. (2018) Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator. Eur Urol Focus :

Showing the most recent 10 out of 989 publications